Menu Search
Equities

Pliant Therapeutics Inc

PLRX:NSQ

Pliant Therapeutics Inc

Actions
  • Price (USD)13.46
  • Today's Change0.48 / 3.70%
  • Shares traded411.22k
  • 1 Year change-5.81%
  • Beta1.0587
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pliant Therapeutics Inc's revenues fell -83.69% from 9.69m to 1.58m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 123.32m to a larger loss of 161.34m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-40.90%
Return on equity-47.52%
Return on investment-43.90%
More ▼

Cash flow in USDView more

In 2023, Pliant Therapeutics Inc increased its cash reserves by 92.13%, or 31.03m. Cash Flow from Financing totalled 274.41m or 17,367.41% of revenues. In addition the company used 116.36m for operations while cash used for investing totalled 127.01m.
Cash flow per share-3.31
Price/Cash flow per share--
Book value per share5.68
Tangible book value per share5.68
More ▼

Balance sheet in USDView more

Pliant Therapeutics Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio10.26
Quick ratio--
Total debt/total equity0.0872
Total debt/total capital0.0802
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.